Skip to main content

Selling a Little for a Big Gain

We'll trim Rada Electronic again and raise our price target. Plus updates on ATRS and SFT.
  • Author:
  • Publish date:
Comments

Rada Electronic Industries (RADA) has been flirting with the $14 level all week (two days). We trimmed this name a week ago when the shares took out our $12 price target and we increased that target to $14. I see a recent trade around $13.83, so I think small action is necessary.

-- We will sell 50 shares of RADA at or close to $13.83, reducing the portfolio's long position to 500 shares. The portfolio will realize a profit of 108% on this small sale, and the weighting of RADA upon the book will be reduced to 2.4%.

-- We are increasing our price target on RADA to $16 from $14. At least now, we'll have the highest target on Wall Street, and we can let it breathe a little.

Antares Pharma

Wednesday morning, Antares Pharma (ATRS) announced that President and CEO Robert F. Apple will participate and host investor meetings at the SVB Leerink (10th) Annual Virtual Global Healthcare Conference to be held from Feb. 22 to Feb. 26 (next week). While updates on sales of both the XYOSTED testosterone treatment and the OTREXUP injection are likely, I would imagine we hear more about the marketing deal for NOCDURNA in the U.S., licensed from Ferring Pharmaceuticals.

Shift Technologies

Also on Wednesday morning, Shift Technologies (SFT) announced that it will report fourth-quarter and full-year 2020 results for the period ending Dec. 31 after the close of business on Monday, March 8. Management will host a conference call and live webcast at 5 p.m. ET to discuss the results and answer questions. Interested investors will be able to reach the call at (833) 614-1395 or (914) 987-7116. The webcast will be broadcast at the company's website.

A consensus of the six analysts that follow Shift are expecting a fourth-quarter loss of $0.42 per shareon revenue of $73 million. There are no year-ago comps, but sequentially these numbers if realized, would be improvements from a third-quarter loss of $0.64 on revenue of $48.9 million (+50.5% q/q).

ADDITIONAL INFORMATION
For current insights go to Actions & Analysis.
Don't miss out on the Weekly Roundups.
View the Portfolio
Get the additional market insights with our Bonus Reports.

YOUR ACCOUNT
To manage your account, click here.

GO MOBILE
Get Stocks Under $10 on your smartphone.
For iPhone, click here.
For Android, click here.

Please remember that Stocks Under $10 is not intended to provide personalized investment advice. DO NOT EMAIL THE SU10 TEAM SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH HE CANNOT PROVIDE.